

Digma Medical

A novel, minimally-invasive Laser therapy for GI ablation

Mission: To empower patients and physicians with safe, simple and effective new therapies for metabolic diseases (Type 2 DM) that dramatically improve quality of life and long-term health outcomes


Market



Failing to Address the Global Epidemic of Type 2 Diabetes:

Type 2 Diabetes is a Growing Health Crisis (350M patients globally)
Majority of Patients are not Achieving Treatment Goals (50% achieve glycemic control targets)
Numerous Challenges to Maintaining Optimal Medical Therapy (Only ~40% of patients are compliant)
GLP1 analogues became a game-changer for obesity & Diabetes (> 40% of patients), but not a sustainable solution
Huge market potential: \$2.5B for Diabetics indication

Anatomy



The Duodenum Plays a Key Role in Regulating Blood Glucose

Bariatric surgeries that bypass the duodenum have been shown to restore glycemic control (90%)
Bariatric surgery is highly invasive, expensive & risky → indicated for a subset of the T2D population
Numerous companies are looking for an effective solution using various technologies affecting the duodenum

Technology




A minimally-invasive, endoscopic ablation of the duodenum

Laser-based ablation device: Adjustable and selective tissue interaction for various anatomies
Interrupts metabolic signaling from the gut, reducing insulin resistance & improving glycemic control
Outpatient procedure in GI suite using standard endoscopy technique
Endoscope insertion → Balloon inflation → Laser activation
Hands-Free; No imaging required; Relatively painless; Controlled ablation; One-time procedure
Maximal efficiency, Minimal damage: Highly controlled & automated procedure with maximal precision.



Company Status

- Strong IP:** 15 granted patents in 4 families (US, EU, China and Japan)
Regulatory: Successfully completed EU registrations; Approved FDA IDE
Proven and validated in human trial: Clinically validated for T2D (35 patients have been treated globally so far)
- 0.8% drop in HbA1c at 12 months for subjects with HbA1c ≥8.5% at baseline with oral treatment
 - Durable reduction in f-glucose of - 22 mg/dL
 - No change in weight (HbA1c reduction is independent)
 - Follow-up for more than a year



Investors



Company is looking for:

- 10M\$ for 2-year workplan:
- EU Sham-control study
 - US Pilot study